The stock of Danish biotech Novo Nordisk was down 2.2% Tuesday, after a study found that the company’s obesity drug Wegovy lags its main rival, Eli Lilly & Co. Inc.’s Mounjaro, in speed and magnitude of weight loss.
Novo Nordisk’s stock slumps after study finds Wegovy lags Lilly’s Mounjaro in speed and scale of weight loss
